Andrew Schmidt

@DrCraigGedye @Chrislabaki1 @DrChoueiri My boyeeeeez! Miss you all

Hey @dr_aschmidt! Wish you were at #ASCOGU23!

Touring @SAiGENCI Level 9 facilities at AHMS Building with Director Designate, @ChrisSweens1

@WeickhardtOnc All insightful - the favourite you taught me is calling patients you are most worried about/recently started on therapy. Have incorporated this is my own practice with much success.

I'm not perfectly doing all of these things for all my patients, but trying to incorporate as much as possible. Being a great doctor is so much more than being great at medicine. Being great at listening and caring so important. Let me know your best tips!

I’ve been working in clinical medicine for many years, and have picked up some habits for rapidly improving patient trust and faith in my care. Here are my top 5 "hacks" that I’ve picked up so far that you might want to try incorporating… (and pls let me know your own)

"Very favorable" risk group of mRCC was presented @ASCOGU21 by @dr_aschmidt We externally validated the novel IMDC risk model in "Turkish Oncology Group Kidney Cancer Consortium" database @DrYukselUrun @DrChoueiri @DrDanielHeng @OncoAlert 👇 clinical-genitourinary-cancer.com/article/S1558-…

@WeickhardtOnc @DrCraigGedye @DrL_Krieger Maturing follow up of TKI/IO trials will continue to be interesting for durability of responders

@dr_aschmidt @DrCraigGedye @DrL_Krieger Interesting to see when TKI/IO reimbursed (hopefully later this year) to see what clinicians in Aus choose; high RR and perhaps less severe IO tox profile IMO will lead to balance between IO/IO and the TKI/IO. Prior adjuvant Rx IO will complicate picture

First line options for ccRCC - Australia has Ipi-Nivo for Int-Poor risk, less options in NZ. Time will uncover what combinations gain reimbursement. Regimen differences aside - patients will need access to benefit from therapy. @WeickhardtOnc @DrCraigGedye @DrL_Krieger

Great summary of TKI adjuvant trials in RCC by @apolo_andrea Only STRAC showed a significant DFS benefit. Despite FDA approval not used widely, with toxicity issues and lack of OS

@Chrislabaki1 @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 7/ While more efforts are still needed, we hope our work helps to provide some answers and useful information to healthcare practitioners and patients, in an effort to better understand COVID-19 in this vulnerable population.

@dr_aschmidt @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 6/ -Patients with haematological malignancies are highly represented among breakthrough infections -Lymphopenia, comorbidities, poor PS, active cancer, and haematological malignancies are associated with poor outcomes in breakthrough infections.

1/ Excited to share our work @COVID19nCCC on Breakthrough COVID-19 in Patients with Cancer @Annals_Oncology Team effort with @Chrislabaki1 @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri ms.spr.ly/6018ZTfLa

@Chrislabaki1 @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 5/ Key messages: -Breakthrough infections in patients with cancer can result in severe outcomes -> never disregard suspicious symptoms or underestimate COVID-19 among vaccinated oncological patients

@dr_aschmidt @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 4/ In an effort to characterize breakthrough infections among oncological patients, we analyzed patients with cancer who experienced COVID-19 infection following vaccination (n=54), compared to an unvaccinated oncological population (n=1,733).

@Chrislabaki1 @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 3/ Previously, lower seroconversion rates have been observed in patients with underlying malignancy compared to non-cancer controls (Goshen-Lago T. et al., JAMA Oncol.), and were more pronounced in patients with hematologic malignancies (Thakkar A. et al., Cancer Cell).

@dr_aschmidt @COVID19nCCC @Annals_Oncology @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri 2/ Patients with cancer have been more susceptible to poor outcomes related to COVID-19. Although vaccination is highly effective for protection against SARS-CoV-2, breakthrough infections can occur. Little is known about who is vulnerable and the associated outcomes.

1/ Thrilled to see our work on #COVID19 vaccination in pts with cancer from #CCC19 published. W/ co-1st authors @dr_aschmidt @Chrislabaki1 C-Y Hsu! @Annals_Oncology @COVID19nCCC The crux of it is that even w/ vaccination, some pts w/ cancer (heme ++) remain at high risk

Congratulations @dr_aschmidt et al for this important work! 👍 💉 😷 🦠

1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co-1st authors @dr_aschmidt, @Chrislabaki1, C-Y. Hsu, @ZiadBakouny and co-seniors: @jeremywarner #YuShyr & @farmakiotis @COVID19nCCC annalsofoncology.org/article/S0923-…

@WeickhardtOnc @ChrisSweens1 @anis_a_hamid @AdiBalasub @MikePowl @MPostow @Cheezborger Looking forward to being able to see my friends and colleagues in person again. Whenever that may be..?

Excited by the upcoming data at #ASCO21 but so sad to miss the opportunity to catch up with OS based friends and colleagues! @ChrisSweens1 @anis_a_hamid @dr_aschmidt @AdiBalasub @mikepowl @MPostow @Cheezborger

@drenriquegrande @DrChoueiri @ASCO @CentroGu @DanaFarber_GU Exciting times as the field moves forward. Looking forward to the plenary @DrChoueiri

🤩🌟 WOW!!! #ASCO21 Plenary session with @DrChoueiri 👑 Definitely can't reach higher. My sincere congrats 👏👏🎩 I'm surrendered to the evidence. Let's see if we should start to offer for adjuvant treatment to our RCC pts. @ASCO @CentroGu @DanaFarber_GU

@DrChoueiri @NatureMedicine @OncoAlert @DanaFarber @DanaFarberNews @DanaFarber_GU @urotoday @OncLive @TargetedOnc @kidneycan @KidneyCancer HIF drugs represent a new class of agent that may be particularly relevant in the post-IO space where patients need new active therapies. Looking forward to the Phase 3 trial and combination strategies.

Just out @NatureMedicine: Inhibition of HIF-2 alpha in RCC with belzutfian (MK-6482) - phase 1 trial and biomarker analysis- 1st study to report on the 2nd gen. HIF-2 inhibitors in pts with metastatic ccRCC!! @OncoAlert A THREAD! nature.com/articles/s4159…

HIF-2α inhibition shows ‘encouraging results’ in kidney cancer trial. Study led by Dana-Farber’s Toni Choueiri, MD (@DrChoueiri), and published in @NatureMedicine looks at belzutifan in patients with metastatic renal cell carcinoma: ms.spr.ly/6012Vg5Sn cc @DanaFarber_GU

@ZiadBakouny @biorxivpreprint @srviswanathan @DrChoueiri @VanAllenLab @DanaFarber @broadinstitute @harvardmed @LabSignoretti @anotherpathres @BraunMDPhD @Chrislabaki1 @ShaanDudani @DrDanielHeng @CarvalhoFilipeL @steinharterjack @ChunLGan @OncoAlert An impressive contribution to the literature from a rising star ⭐️ congratulations @ZiadBakouny

1/ Just posted on @biorxivpreprint! Thrilled be sharing our work on translocation Renal Cell Carcinoma (tRCC). Huge thanks to mentors @srviswanathan, @DrChoueiri & @VanAllenLab & all co-authors. @DanaFarber @broadinstitute @harvardmed A Thread (1/15)! biorxiv.org/content/10.110…

Recent IO trials have not progressed the field much in prostate cancer outside of MSI. Thank you @xiaoweimd @DanaFarber_GU summarising upcoming IO trials - buff.ly/3r44vvi

Fantastic summary from @ChrisSweens1 summarising mHSPC data for Docetaxel at the 20th Biennial Course in Urologic Oncology. Volume and time to mets refine benefit @Chrislabaki1 @ZiadBakouny